As the global burden of type 2 diabetes and obesity continues to rise, new treatment solutions are gaining traction. Tirzepatide, the world’s first dual GLP-1 and GIP receptor agonist, has quickly emerged as a game-changer since its FDA approval in 2022, showing unmatched efficacy in both glycemic control and weight loss. ✅ What is Tirzepatide? […]
